Evidence map›Paper›PMID 26032724›Full record

ArticleJournal of the National Cancer Institute2015

Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study.

James J Goedert, Gieira Jones, Xing Hua, Xia Xu, Guoqin Yu, Roberto Flores, Roni T Falk, Mitchell H Gail, Jianxin Shi, Jacques Ravel and 1 more

4 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 237 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
237citing papers in PubMed, 6 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01461070 completednot on this map

BRANCH:Fecal Microbiota Among Participants in a Pre-paid Health Plan

TypeobservationalSponsorNational Cancer Institute (NCI)Ran2011 to 2020Enrolled175ConditionsBreast Neoplasms
NCT03760653 nawithdrawnnot on this mapstarted 2018, after this paper: background citation

Physical Activity Along With a Probiotic for the Immune System and Quality of Life Improvement in Breast Cancer Survivor: A Randomised Controlled Pilot Study

TypeinterventionalSponsorUniversidad Europea de MadridRan2018 to 2019Enrolled0ConditionsBreast Cancer FemalesArmsPhysical Exercise and probiotic group, Probiotic group, Placebo group
NCT05030519 unknown statusnot on this mapstarted 2021, after this paper: background citation

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer

TypeobservationalSponsorZhejiang Cancer HospitalRan2021 to 2022Enrolled50ConditionsBreast CancerArmsPyrotinib
NCT07653698 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of Cancer Cachexia and Analysis of Gut Microbiota in Patients With Breast Cancer Receiving Home Care

TypeinterventionalSponsorFondazione ANT Franco Pannuti ETSRan2026 to 2028Enrolled140ConditionsBreast Cancer, Cancer CachexiaArmsProbiotic Mixture, Placebo
3 · Its place in the literature

Who cites it

237 citing papers in PubMed, 6 syntheses or guidelines pooled it, 384 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. The Human Microbiome in Relation to Cancer Risk: A Systematic Review of Epidemiologic Studies.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. The Role of Selected Bacteria in Breast Cancer Initiation and Development.International journal of molecular sciences · 2026
    Review
  15. Gut Microbiota and Extraintestinal Cancers: Mechanistic Insights and Microbiome-Targeted Interventions.JGH open : an open access journal of gastroenterology and hepatology · 2026
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

177 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

James J GoedertDivision of Cancer Epidemiology and Genetics (JJG, GJ, XH, GY, RF, RTF, MHG, JS) and Division of Cancer Prevention (RF), National Cancer Institute, Bethesda, MD; Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (XX); Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD (JR); Institute for Health Research, Kaiser Permanente Colorado, Denver, CO (HSF). goedertj@mail.nih.gov.
Gieira JonesDivision of Cancer Epidemiology and Genetics (JJG, GJ, XH, GY, RF, RTF, MHG, JS) and Division of Cancer Prevention (RF), National Cancer Institute, Bethesda, MD; Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (XX); Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD (JR); Institute for Health Research, Kaiser Permanente Colorado, Denver, CO (HSF).
Xing HuaDivision of Cancer Epidemiology and Genetics (JJG, GJ, XH, GY, RF, RTF, MHG, JS) and Division of Cancer Prevention (RF), National Cancer Institute, Bethesda, MD; Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (XX); Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD (JR); Institute for Health Research, Kaiser Permanente Colorado, Denver, CO (HSF).
Xia XuDivision of Cancer Epidemiology and Genetics (JJG, GJ, XH, GY, RF, RTF, MHG, JS) and Division of Cancer Prevention (RF), National Cancer Institute, Bethesda, MD; Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (XX); Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD (JR); Institute for Health Research, Kaiser Permanente Colorado, Denver, CO (HSF).
Guoqin YuDivision of Cancer Epidemiology and Genetics (JJG, GJ, XH, GY, RF, RTF, MHG, JS) and Division of Cancer Prevention (RF), National Cancer Institute, Bethesda, MD; Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (XX); Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD (JR); Institute for Health Research, Kaiser Permanente Colorado, Denver, CO (HSF).
Roberto FloresDivision of Cancer Epidemiology and Genetics (JJG, GJ, XH, GY, RF, RTF, MHG, JS) and Division of Cancer Prevention (RF), National Cancer Institute, Bethesda, MD; Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (XX); Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD (JR); Institute for Health Research, Kaiser Permanente Colorado, Denver, CO (HSF).
Roni T FalkDivision of Cancer Epidemiology and Genetics (JJG, GJ, XH, GY, RF, RTF, MHG, JS) and Division of Cancer Prevention (RF), National Cancer Institute, Bethesda, MD; Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (XX); Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD (JR); Institute for Health Research, Kaiser Permanente Colorado, Denver, CO (HSF).
Mitchell H GailDivision of Cancer Epidemiology and Genetics (JJG, GJ, XH, GY, RF, RTF, MHG, JS) and Division of Cancer Prevention (RF), National Cancer Institute, Bethesda, MD; Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (XX); Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD (JR); Institute for Health Research, Kaiser Permanente Colorado, Denver, CO (HSF).
Jianxin ShiDivision of Cancer Epidemiology and Genetics (JJG, GJ, XH, GY, RF, RTF, MHG, JS) and Division of Cancer Prevention (RF), National Cancer Institute, Bethesda, MD; Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (XX); Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD (JR); Institute for Health Research, Kaiser Permanente Colorado, Denver, CO (HSF).
Jacques RavelDivision of Cancer Epidemiology and Genetics (JJG, GJ, XH, GY, RF, RTF, MHG, JS) and Division of Cancer Prevention (RF), National Cancer Institute, Bethesda, MD; Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (XX); Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD (JR); Institute for Health Research, Kaiser Permanente Colorado, Denver, CO (HSF).
Heather Spencer FeigelsonDivision of Cancer Epidemiology and Genetics (JJG, GJ, XH, GY, RF, RTF, MHG, JS) and Division of Cancer Prevention (RF), National Cancer Institute, Bethesda, MD; Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (XX); Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD (JR); Institute for Health Research, Kaiser Permanente Colorado, Denver, CO (HSF).
University of Maryland, Baltimore · USDivision of Cancer Epidemiology and GeneticsNational Cancer Institute · USFrederick National Laboratory for Cancer Research · USLeidos (United States) · US

Funding

Microbes and Human MalignanciesZIACP010214 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI VOGTMANN, EMILY · 2010 to 2021
$5.5M
Intramural NIH HHSNCI NIH HHS Z01CP010214
6 · The paper itself

Abstract

We investigated whether the gut microbiota differed in 48 postmenopausal breast cancer case patients, pretreatment, vs 48 control patients. Microbiota profiles in fecal DNA were determined by Illumina sequencing and taxonomy of 16S rRNA genes. Estrogens were quantified in urine. Case-control comparisons employed linear and unconditional logistic regression of microbiota α-diversity (PD_whole tree) and UniFrac analysis of β-diversity, with two-sided statistical tests. Total estrogens correlated with α-diversity in control patients (Spearman Rho = 0.37, P = .009) but not case patients (Spearman Rho = 0.04, P = .77). Compared with control patients, case patients had statistically significantly altered microbiota composition (β-diversity, P = .006) and lower α-diversity (P = .004). Adjusted for estrogens and other covariates, odds ratio of cancer was 0.50 (95% confidence interval = 0.30 to 0.85) per α-diversity tertile. Differences in specific taxa were not statistically significant when adjusted for multiple comparisons. This pilot study shows that postmenopausal women with breast cancer have altered composition and estrogen-independent low diversity of their gut microbiota. Whether these affect breast cancer risk and prognosis is unknown.

Indexed as

MicrobiotaPostmenopauseAgedBreast NeoplasmsCase-Control StudiesEstrogensFecesFemaleHumansLinear ModelsLogistic ModelsMiddle AgedOdds RatioPilot ProjectsPredictive Value of TestsPrognosisEstrogensRNA, Ribosomal, 16S

Identifiers

PMID26032724
PMCPMC4554191
OpenAlexW2171437158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.